<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Invasive group A streptococcal infection and toxic shock syndrome: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dennis L Stevens, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R Wessels, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Group A <em>Streptococcus </em>(GAS; <em>Streptococcus pyogenes</em>) is an aerobic gram-positive coccus that causes a broad array of infections. GAS is most commonly associated with pharyngitis or skin and soft tissue infection; these are not typically associated with invasive infection.</p><p>Less commonly, GAS causes invasive disease; invasive GAS infection refers to infection in the setting of culture isolation of GAS from a normally sterile site (most commonly blood; less commonly pleural, pericardial, joint, or cerebrospinal fluid) [<a href="#rid1">1,2</a>].</p><p>Forms of invasive GAS infection include [<a href="#rid1">1,3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Necrotizing soft tissue infection (see  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy-associated infection (see  <a class="medical medical_review" href="/z/d/html/97358.html" rel="external">"Pregnancy-related group A streptococcal infection"</a> and  <a class="medical medical_review" href="/z/d/html/5488.html" rel="external">"Postpartum endometritis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia (may occur in association with or in the absence of another infection)</p><p></p><p>Toxic shock syndrome (TSS) occurs as a complication of invasive GAS disease in approximately one-third of cases [<a href="#rid5">5</a>].</p><p>The treatment and prevention of invasive GAS infection will be reviewed here. Issues related to the epidemiology, clinical manifestations, and diagnosis of invasive GAS infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Issues related to GAS bacteremia in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6068.html" rel="external">"Invasive group A streptococcal infections in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H614415484"><span class="h2">Streptococcal toxic shock syndrome</span><span class="headingEndMark"> — </span>Management of streptococcal TSS includes treatment of septic shock and associated complications, surgical debridement of infection (if warranted), antimicrobial therapy, and administration of intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>. Such cases frequently require coordinated care from a team including individuals with clinical expertise in critical care, surgery, and infectious disease.</p><p class="headingAnchor" id="H3"><span class="h3">Management of septic physiology</span><span class="headingEndMark"> — </span>Streptococcal TSS is associated with a diffuse capillary leak syndrome with associated hypotension, hypoalbuminemia, and third spacing. Large quantities of intravenous (IV) fluids (up to 10 to 20 L/day) and vasopressors may be necessary to maintain perfusion. Because TSS can cause sepsis-associated cardiomyopathy, echocardiography can be helpful, particularly since patients with cardiomyopathy may be particularly susceptible to vasopressor-associated symmetrical gangrene of the extremities [<a href="#rid6">6</a>]. The approach to management of septic shock is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Surgical debridement</span><span class="headingEndMark"> — </span>Streptococcal TSS may occur in the setting of necrotizing soft tissue infection. In such cases, early aggressive surgical intervention is critical. Issues related to surgical management of necrotizing soft tissue infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108059.html" rel="external">"Surgical management of necrotizing soft tissue infections"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Antibiotic therapy</span><span class="headingEndMark"> — </span>Empiric antimicrobial therapy should be initiated pending culture results; thereafter, antimicrobial therapy should be tailored accordingly. Regimens for empiric and tailored therapy are summarized below. (See <a class="local">'Empiric therapy'</a> below and <a class="local">'Tailored therapy'</a> below.)</p><p class="headingAnchor" id="H15604631"><span class="h4">General principles</span><span class="headingEndMark"> — </span>In general, antimicrobial treatment of streptococcal TSS consists of a beta-lactam agent (which inhibits cell wall synthesis) in combination with <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (which inhibits protein synthesis).</p><p><em>S. pyogenes</em> is exquisitely susceptible to beta-lactam antibiotics, which are bactericidal; however, penicillin monotherapy has been associated with high morbidity and mortality in the setting of group A <em>Streptococcus </em>(GAS) infections associated with toxin production (eg, TSS and necrotizing soft tissue infection) [<a href="#rid2">2,5,7-11</a>].</p><p>Studies of experimental infection have noted an association between penicillin monotherapy and treatment failure in the setting of high inoculum [<a href="#rid12">12-16</a>]. In general, beta-lactam antibiotics are believed to be most effective against rapidly growing bacteria. Therefore, the efficacy is likely greatest in the early stages of infection when organisms are multiplying quickly and may be diminished as organism concentrations increase and the rate of bacterial growth slows. In the setting of deep-seated infection, the concentration of organisms may be sufficiently high to reduce the effectiveness of beta-lactam antibiotics [<a href="#rid12">12</a>]. In addition, diminished efficacy of penicillin monotherapy in the setting of high inoculum has been attributed to the available numbers of penicillin-binding proteins (PBPs) on the organism surface that are available at various points during the phases of bacterial growth. In one in vitro study, fewer PBPs were observed during stationary-phase growth [<a href="#rid15">15</a>].</p><p>For these reasons, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> should be used together with a beta-lactam antibiotic for treatment of streptococcal TSS; the beta-lactam antibiotic is included in case the infection is caused by an isolate that is resistant to clindamycin. Other potential advantages of clindamycin for treatment of streptococcal TSS include: (1) clindamycin efficacy is not affected by inoculum size or stage of growth, (2) clindamycin suppresses bacterial toxin production, (3) clindamycin is associated with a longer postantibiotic effect than beta-lactam agents, and (4) clindamycin suppresses synthesis of PBPs, which are involved in cell wall synthesis and degradation (in addition to serving as binding targets for penicillin) [<a href="#rid15">15,17-20</a>]. There are no additive, synergistic, or antagonistic effects of clindamycin and penicillin in vitro.</p><p>The above approach to use of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> is supported by observational studies [<a href="#rid21">21-24</a>]. As an example, in a retrospective study including 1079 patients with invasive GAS infection treated with beta-lactam antibiotics (of whom 343 received adjunctive clindamycin), use of adjunctive clindamycin was associated with lower mortality (6.5 versus 11 percent; adjusted odds ratio 0.44 [95% CI 0.23-0.81]); this survival benefit was maintained even among the 661 patients without shock or necrotizing fasciitis (2.6 versus 6.1 percent; aOR 0.40 [95% CI 0.15-0.91]) [<a href="#rid24">24</a>].</p><p>Targeted antibiotic therapy should be guided by antibiotic susceptibility testing. There have been reports of increasing frequency of GAS isolates with inducible or constitutive resistance to <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (15 percent in one study) and other macrolide-lincosamide-streptogramin B (MLS) antibiotics [<a href="#rid25">25-27</a>]. In the United States in the early 2000s, clindamycin resistance occurred in less than 1 percent of isolates overall [<a href="#rid25">25</a>], but this increased to 15 percent between 2011 and 2015 [<a href="#rid28">28</a>]. Recent preliminary data from the United States Centers for Disease Control and Prevention (CDC) Active Bacterial Core surveillance program indicate this trend has continued, with invasive isolates from 2021 showing resistance rates to clindamycin and macrolides of 34.3 and 34.6 percent, respectively [<a href="#rid29">29</a>]. An increasing number of GAS isolates with constitutive or inducible resistance to MLS antibiotics, including clindamycin, have been identified in Europe [<a href="#rid26">26</a>]. In China, clindamycin resistance has been observed in as many as 94 percent of isolates [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H15604893"><span class="h4">Antibiotic regimens</span><span class="headingEndMark"> — </span>Empiric antimicrobial therapy should be initiated pending culture results; thereafter, antimicrobial therapy should be tailored accordingly.</p><p class="headingAnchor" id="H19825113"><span class="h5">Empiric therapy</span><span class="headingEndMark"> — </span>At initial presentation, streptococcal TSS cannot be distinguished immediately from sepsis syndromes due to other pathogens. Therefore, empiric therapy should consist of broad-spectrum antibiotic treatment to cover not only GAS, but also <em>Staphylococcus aureus (</em>including methicillin-resistant <em>S. aureus</em>) as well as gram-negative bacilli.</p><p>For empiric treatment of suspected streptococcal TSS, we favor the following regimen (pending culture results):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (adults: 900 mg IV every eight hours; children: 30 to 40 mg/kg per day IV, divided every 6 to 8 hours; maximum daily dose 2.7 g)</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> (adults: dosing summarized in table  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 1</a>); children: 15 mg/kg/dose IV every 6 to 8 hours, usual maximum 4 g per day)</p><p></p><p class="bulletIndent1"><strong>PLUS</strong> one of the following:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A carbapenem (adults: <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> 500 mg IV every 6 hours; higher dosing of 1 g every 6 to 8 hours may be used for patients with obesity, recent broad-spectrum antibiotic treatment, or recent colonization with resistant organisms OR <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> 1 g IV every 8 hours; children: imipenem 15 to 25 mg/kg/dose every 6 hours [maximum 4 g per day] or meropenem 20 mg/kg/dose every 8 hours [maximum 1 g per dose])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A combination drug containing a penicillin plus beta-lactamase inhibitor (adults: <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> 4.5 g every 6 hours; children: 100 mg/kg <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>/kg/dose IV every 6 hours or 100 mg/kg piperacillin/kg/dose IV every 8 hours [maximum 16 g piperacillin per day])</p><p></p><p>Patients with known hypersensitivity to penicillin may be treated with <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> plus <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus a carbapenem. If carbapenems are not tolerated, clindamycin plus vancomycin plus a fluoroquinolone may be used.</p><p class="headingAnchor" id="H9"><span class="h5">Tailored therapy</span><span class="headingEndMark"> — </span>Once a diagnosis of streptococcal TSS is established, treatment consists of:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (adults: 900 mg IV every eight hours; children: 30 to 40 mg/kg IV per day, divided every six to eight hours; maximum daily dose 2.7 g)</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">Penicillin G</a> (adults: 4 million units IV every four hours; children: 200,000 to 400,000 units/kg IV per day, divided every four to six hours in patients with normal renal function; maximum pediatric daily dose 24 million units).</p><p></p><p class="bulletIndent1">For patients with beta-lactam hypersensitivity (in the absence of anaphylaxis), alternatives to penicillin include <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (adults: 1 to 2 g IV every 12 hours; children: 50 mg/kg IV every 12 to 24 hours [maximum dose 2 g every 12 hours]), <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> (adults: 2 g IV every 8 hours; children: 50 to 100 mg/kg/day IV divided every 8 hours [maximum daily dose 12 g/day]).</p><p></p><p class="bulletIndent1">For patients with history of anaphylaxis to beta-lactams, alternatives to penicillin include <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (adults: dosing summarized in table  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 1</a>); children: 45 mg/kg/day IV in three divided doses) or <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (adults: 6 mg/kg IV every 24 hours; children: 10 mg/kg IV once daily [&lt;6 years of age], 7 mg/kg IV once daily [7 to 11 years of age], 4 to 6 mg/kg IV once daily [&gt;12 years of age]).</p><p></p><p>Once antibiotic susceptibility data are available, the approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with streptococcal TSS due to GAS isolates susceptible to <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> – In general, combination therapy with penicillin and clindamycin should be continued until patients are clinically and hemodynamically stable (ie, 48 to 72 hours); thereafter, clindamycin therapy should be discontinued and the patient should be maintained on penicillin monotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with streptococcal TSS due to GAS isolates resistant to <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> – Combination therapy with penicillin and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> (adults and children ≥12 years: 600 mg IV every 12 hours; children &lt;12 years of age: 10 mg/kg IV every 8 hours [maximum 600 mg/dose]) or <a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a> (adults: 200 mg IV every 24 hours; not US Food and Drug Administration approved for use in children) should be continued until patients are clinically and hemodynamically stable (ie, 48 to 72 hours) [<a href="#rid31">31,32</a>]. Thereafter, penicillin should be continued (linezolid or tedizolid should be discontinued). </p><p></p><p>The above approach is based on retrospective and animal data.</p><p class="headingAnchor" id="H10"><span class="h4">Duration of therapy</span><span class="headingEndMark"> — </span>There are no clinical studies addressing the optimal duration of antibiotic therapy in streptococcal TSS. The duration of antibiotic therapy should be tailored to individual patient circumstances, including the source of infection and clinical response to treatment.</p><p>Patients with bacteremia should be treated for at least 14 days. In patients with complicating deep-seated infection (such as necrotizing fasciitis), length of therapy depends on the clinical course and the adequacy of surgical debridement; therapy is usually continued for 14 days from the last positive culture obtained during surgical debridement. (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Adjunctive therapy</span><span class="headingEndMark"> — </span>Adjunctive therapies evaluated for treatment of invasive GAS infection include intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), hyperbaric oxygen, and anti-tumor necrosis factor (TNF) antibody.</p><p class="headingAnchor" id="H12"><span class="h4">Intravenous immune globulin</span><span class="headingEndMark"> — </span>We favor administration of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> for treatment of patients with streptococcal TSS. Dosing (for adults and children) consists of 1 g/kg on day 1, followed by 0.5 g/kg on days 2 and 3.</p><p>This approach is supported by a 2018 meta-analysis including five studies of patients with streptococcal TSS treated with <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (one randomized and four nonrandomized), in which use of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> was associated with 30-day reduction in mortality (33.7 to 15.7 percent) [<a href="#rid33">33</a>]. Prior data from retrospective studies and statistically underpowered prospective trials have been inconclusive on the efficacy of IVIG for streptococcal TSS [<a href="#rid23">23,34-36</a>].</p><p>The proposed rationale for use of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in streptococcal TSS is to boost antibody levels via passive immunity in the setting of overwhelming infection. Several mechanisms have been suggested, including opsonization of GAS for phagocytic killing, neutralization of streptococcal toxins, inhibition of T cell proliferation, and inhibition of inflammatory cytokines such as TNF-alpha and interleukin 6 [<a href="#rid37">37-42</a>]. Some IVIG preparations contain neutralizing antibodies against several streptococcal toxins such as the pyrogenic exotoxins (streptococcal pyrogenic exotoxin [SPE]A, SPEB, SPEC, and mitogenic factor), streptolysin O, and DNase B; specific antibody preparations are not commercially available [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p>Differences between neutralizing activities have been observed in different batches of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> from different manufacturers. In one study, Vigam-S (obtained from plasma collected from donors in the United States) had consistently high inhibition against all GAS superantigens, while European IVIG preparations had the lowest activity; an Australian preparation had intermediate activity [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H15611175"><span class="h4">Other therapies</span><span class="headingEndMark"> — </span>The use of hyperbaric oxygen has been reported in a small number of patients with streptococcal TSS [<a href="#rid45">45</a>]. There are no controlled trials, and the efficacy of this treatment is not known. (See  <a class="medical medical_review" href="/z/d/html/326.html" rel="external">"Hyperbaric oxygen therapy"</a>.)</p><p>Use of anti-TNF antibody has been studied in an animal model of streptococcal TSS with promising results [<a href="#rid46">46</a>]; further study is needed.</p><p class="headingAnchor" id="H235752098"><span class="h2">Invasive GAS infection (in absence of toxic shock)</span></p><p class="headingAnchor" id="H1856459473"><span class="h3">Bacteremia</span><span class="headingEndMark"> — </span>The approach to treatment of bacteremia that occurs in association with other clinical manifestation(s) should be guided by the primary presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>Issues related to treatment of necrotizing soft tissue infections are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections", section on 'Antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Issues related to treatment of pregnancy-associated GAS infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/97358.html" rel="external">"Pregnancy-related group A streptococcal infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Issues related to treatment of streptococcal toxic shock syndrome are discussed above. (See <a class="local">'Streptococcal toxic shock syndrome'</a> above.)</p><p></p><p>General principles related to antimicrobial treatment of streptococcal TSS are summarized above. (See <a class="local">'General principles'</a> above.)</p><p>For initial treatment of GAS bacteremia (in the absence of shock, organ failure, or necrotizing infection), we favor combination therapy with <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>; penicillin G monotherapy is a reasonable alternative. Clindamycin suppresses toxin production and reduces the risk of treatment failure. This approach is based on retrospective and animal data [<a href="#rid13">13,14,22</a>].</p><p>Issues related to drug dosing, beta-lactam hypersensitivity, and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> are summarized above. (See <a class="local">'Tailored therapy'</a> above.)</p><p>The optimal duration of antibiotic therapy for GAS bacteremia is uncertain; data are limited. For patients initially treated with combination therapy who do not have shock, organ failure, or necrotizing infection, discontinuation of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> within 48 hours is reasonable. Thereafter, penicillin monotherapy should be continued to complete at least 14 days of treatment. The duration of antibiotic therapy should be tailored to individual patient circumstances, including the source of infection and clinical response to treatment.</p><p>It is uncertain whether intravenous therapy is required for the entire duration of antibiotic therapy. For patients with GAS bacteremia (in the absence of shock, organ failure, or necrotizing infection), it may be reasonable to complete the course of antibiotic therapy with an oral agent following completion of surgical debridement (if needed), clearance of bacteremia, and resolution of systemic signs of infection. Oral regimens are summarized in the table  (<a class="graphic graphic_table graphicRef120758" href="/z/d/graphic/120758.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3722927195"><span class="h3">Respiratory tract infection</span><span class="headingEndMark"> — </span>The approach to treatment of respiratory tract infection due to GAS is the same as the approach to treatment of GAS bacteremia. (See <a class="local">'Bacteremia'</a> above.)</p><p>Pleural effusion associated with GAS pneumonia often represents an empyema. Patients with pleural effusion should undergo thoracentesis; if purulent fluid is encountered, it should be drained promptly to control infection and to prevent complications from pleural adhesions. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The mortality rate for invasive GAS infection ranges from 25 to 48 percent [<a href="#rid1">1,5,8,47-49</a>]. In one series including 67 cases of GAS bacteremia, shock was the most important predictor of mortality (79 versus 16 percent) [<a href="#rid47">47</a>].</p><p>The mortality rate for streptococcal TSS ranges from 30 to 79 percent [<a href="#rid4">4,5,50-53</a>]. Mortality rates are lower in children than adults. One series including 144 children noted a mortality rate of 18 percent [<a href="#rid54">54</a>]; another series including 192 children noted a mortality of 4 percent [<a href="#rid36">36</a>].</p><p>In one retrospective study including 66 patients with streptococcal TSS comparing physical and laboratory findings of patients who survived with patients who died, patients who died had lower mean systolic blood pressure (99 versus 120 mmHg), lower mean body temperature (37.0 versus 38.3ºC), higher mean serum creatinine (3.0 versus 2.0 mg/dL), lower mean white blood cell count (1000 versus 16,000 cells per microL), and lower platelet count (120,000 versus 170,000 cells per microL) [<a href="#rid53">53</a>].</p><p>Mortality due to streptococcal TSS is substantially higher than mortality due to staphylococcal TSS. Streptococcal TSS is frequently associated with deep soft tissue infection, so source control can be difficult. In addition, streptococcal TSS occurs more frequently among patients with underlying medical conditions than staphylococcal TSS. (See  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a>.)</p><p class="headingAnchor" id="H2840727093"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H24997268"><span class="h2">Prophylaxis for contacts</span><span class="headingEndMark"> — </span>Group A <em>Streptococcus </em>(GAS) is a highly contagious organism; close contacts of a case of invasive GAS infection have a high likelihood of becoming colonized with a virulent strain [<a href="#rid55">55</a>]. The risk of subsequent invasive GAS disease among household contacts of persons with invasive GAS infections is higher (200- to 2000-fold) than the risk among the general population [<a href="#rid56">56</a>], but subsequent invasive GAS infections are rare [<a href="#rid57">57</a>].</p><p>The optimal approach to postexposure prophylaxis for prevention of invasive GAS infection is uncertain. The goal is clearance of asymptomatic colonization to reduce the likelihood of a secondary infection.</p><p>Decisions regarding administration of prophylaxis depend on the degree of exposure and the immune status of the contact. Significant exposures include close family members, patients who are kissing or sleeping in the same bed, and caretakers who spend many hours daily with an infected individual. Prophylaxis is warranted for contacts who are immunosuppressed, pregnant, have had recent surgery, or have any type of open wound.</p><p>The regimen for prophylaxis consists of penicillin (adults: 250 mg orally four times daily for 10 days; children: 25 mg/kg/dose [maximum 250 mg per dose] orally four times daily for 10 days). Alternative regimens for individuals with beta-lactam hypersensitivity are listed below. Before choosing an alternative antibiotic, susceptibility of the index patient isolate to the selected drug should be confirmed.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (adults: 20 mg/kg/day orally [maximum daily dose 900 mg] in three divided doses for 10 days; children: 25 to 30 mg/kg/day orally [maximum daily dose 900 mg])</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> (adults and children: 12 mg/kg/day [maximum daily dose 500 mg] as a single daily dose for five days).</p><p></p><p class="headingAnchor" id="H2611459617"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>In addition to standard precautions, patients with invasive GAS infection associated with soft tissue involvement warrant droplet precautions as well as contact precautions; patients with streptococcal toxic shock or streptococcal pneumonia warrant droplet precautions [<a href="#rid58">58</a>]. Droplet and contact precautions may be discontinued after the first 24 hours of antimicrobial therapy.</p><p>Strategies for management of GAS outbreaks in health care facilities include adherence to infection control practices (particularly hand washing), and attentive wound care [<a href="#rid59">59</a>]. If more than one case of invasive GAS infection occurs in a six-month period, an epidemiologic work-up is indicated (including cultures of specimens from epidemiologically linked health care workers) [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H2233811917"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of illness</strong> – Forms of invasive group A streptococcal (GAS) infection include necrotizing soft tissue infection, pregnancy-associated infection, bacteremia, and respiratory tract infection. Toxic shock syndrome (TSS) occurs as a complication of invasive GAS disease in approximately one-third of cases. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Issues related to treatment of necrotizing soft tissue infections and pregnancy-related GAS infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/108059.html" rel="external">"Surgical management of necrotizing soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/97358.html" rel="external">"Pregnancy-related group A streptococcal infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GAS toxic shock syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General principles of treatment</strong> – Management of streptococcal TSS includes treatment of septic shock and associated complications, surgical debridement of infection (if warranted), and antimicrobial therapy. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a> and  <a class="medical medical_review" href="/z/d/html/108059.html" rel="external">"Surgical management of necrotizing soft tissue infections"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic selection</strong> – We typically use the following antibiotic regimens; dosing is summarized above (see <a class="local">'Antibiotic regimens'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Empiric therapy</strong> – For patients with suspected streptococcal TSS, we favor treatment with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, and either a combination drug containing a penicillin plus beta-lactamase inhibitor or a carbapenem. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Definitive therapy</strong> – For patients with an established diagnosis of streptococcal TSS, we suggest treatment with combination antibiotic therapy including <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> and an antibiotic that suppresses protein synthesis such as <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (rather than penicillin G alone) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given the importance of toxin production in the pathogenesis of streptococcal TSS. Antibiotic therapy should be adjusted based on antibiotic susceptibility once available. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – The duration should be tailored to individual patient circumstances, including the source of infection and clinical response to treatment. (See <a class="local">'Tailored therapy'</a> above and <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjunctive therapy</strong> – For patients with streptococcal TSS, we suggest administering intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Intravenous immune globulin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GAS bacteremia</strong> – For initial treatment of GAS bacteremia (in the absence of shock, organ failure, or necrotizing infection), we suggest combination therapy with <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> and an antibiotic that suppresses protein synthesis such as <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); penicillin G monotherapy is a reasonable alternative. (See <a class="local">'Bacteremia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Waddington CS, Snelling TL, Carapetis JR. Management of invasive group A streptococcal infections. J Infect 2014; 69 Suppl 1:S63.</a></li><li><a class="nounderline abstract_t">Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Streptococcus Disease, Invasive, Group A (GAS) (Streptococcus pyogenes)
1995 Case Definition. https://ndc.services.cdc.gov/conditions/streptococcus-disease-invasive-group-a/ (Accessed on September 17, 2018).</li><li><a class="nounderline abstract_t">Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 2007; 45:450.</a></li><li><a class="nounderline abstract_t">Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1.</a></li><li><a class="nounderline abstract_t">Bolz DD, Li Z, McIndoo ER, et al. Cardiac myocyte dysfunction induced by streptolysin O is membrane pore and calcium dependent. Shock 2015; 43:178.</a></li><li><a class="nounderline abstract_t">Group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med 1989; 321:1545.</a></li><li><a class="nounderline abstract_t">Martin PR, Høiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990; 22:421.</a></li><li><a class="nounderline abstract_t">Hríbalová V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988; 108:772.</a></li><li><a class="nounderline abstract_t">Adams EM, Gudmundsson S, Yocum DE, et al. Streptococcal myositis. Arch Intern Med 1985; 145:1020.</a></li><li><a class="nounderline abstract_t">Köhler W. Streptococcal toxic shock syndrome. Zentralbl Bakteriol 1990; 272:257.</a></li><li><a class="nounderline abstract_t">EAGLE H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389.</a></li><li><a class="nounderline abstract_t">Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: New concepts in antibiotic treatment. Int J Antimicrob Agents 1994; 4:297.</a></li><li><a class="nounderline abstract_t">Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167:1401.</a></li><li><a class="nounderline abstract_t">Yan S, Mendelman PM, Stevens DL. The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett 1993; 110:313.</a></li><li><a class="nounderline abstract_t">Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular-weight penicillin-binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes. J Infect Dis 1994; 170:609.</a></li><li><a class="nounderline abstract_t">Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987; 31:213.</a></li><li><a class="nounderline abstract_t">Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67:1249.</a></li><li><a class="nounderline abstract_t">Mascini EM, Jansze M, Schouls LM, et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001; 18:395.</a></li><li><a class="nounderline abstract_t">Wong CJ, Stevens DL. Serious group a streptococcal infections. Med Clin North Am 2013; 97:721.</a></li><li><a class="nounderline abstract_t">Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18:1096.</a></li><li><a class="nounderline abstract_t">Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 2014; 59:358.</a></li><li><a class="nounderline abstract_t">Babiker A, Li X, Lai YL, et al. Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis 2021; 21:697.</a></li><li><a class="nounderline abstract_t">Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599.</a></li><li><a class="nounderline abstract_t">Gooskens J, Neeling AJ, Willems RJ, et al. Streptococcal toxic shock syndrome by an iMLS resistant M type 77 Streptococcus pyogenes in the Netherlands. Scand J Infect Dis 2005; 37:85.</a></li><li><a class="nounderline abstract_t">Chen I, Kaufisi P, Erdem G. Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii. J Clin Microbiol 2011; 49:439.</a></li><li><a class="nounderline abstract_t">DeMuri GP, Sterkel AK, Kubica PA, et al. Macrolide and Clindamycin Resistance in Group a Streptococci Isolated From Children With Pharyngitis. Pediatr Infect Dis J 2017; 36:342.</a></li><li class="breakAll">ABCs Bact Facts Interactive Data Dashboard. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/abcs/bact-facts-interactive-dashboard.html. (Accessed on March 15, 2023).</li><li><a class="nounderline abstract_t">Lu B, Fang Y, Fan Y, et al. High Prevalence of Macrolide-resistance and Molecular Characterization of Streptococcus pyogenes Isolates Circulating in China from 2009 to 2016. Front Microbiol 2017; 8:1052.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bryant AE. Necrotizing Soft-Tissue Infections. N Engl J Med 2017; 377:2253.</a></li><li class="breakAll">Bryant AE, Aldape MJ, Bayer CR, et al.  Efficacy of tedizolid in experimental myonecrosiss caused by erythromycin/clindamycin-sensitive and-resistant group A streptococcus. Proceedings and Abstracts of 2016 IDWeek, New Orleans, LA, October 26-30, 2016.</li><li><a class="nounderline abstract_t">Parks T, Wilson C, Curtis N, et al. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis. Clin Infect Dis 2018; 67:1434.</a></li><li><a class="nounderline abstract_t">Kadri SS, Swihart BJ, Bonne SL, et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis 2017; 64:877.</a></li><li><a class="nounderline abstract_t">Linnér A, Darenberg J, Sjölin J, et al. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014; 59:851.</a></li><li><a class="nounderline abstract_t">Shah SS, Hall M, Srivastava R, et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009; 49:1369.</a></li><li><a class="nounderline abstract_t">Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057.</a></li><li><a class="nounderline abstract_t">Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64:5395.</a></li><li><a class="nounderline abstract_t">Darenberg J, Söderquist B, Normark BH, Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38:836.</a></li><li><a class="nounderline abstract_t">Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800.</a></li><li><a class="nounderline abstract_t">Shimozato T, Iwata M, Tamura N. Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 1990; 58:1384.</a></li><li><a class="nounderline abstract_t">Achiron A, Margalit R, Hershkoviz R, et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 1994; 93:600.</a></li><li><a class="nounderline abstract_t">Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31.</a></li><li><a class="nounderline abstract_t">Schrage B, Duan G, Yang LP, et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006; 43:743.</a></li><li><a class="nounderline abstract_t">Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bryant AE, Hackett SP, et al. Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996; 173:619.</a></li><li><a class="nounderline abstract_t">Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge--a review of 67 episodes. Q J Med 1988; 68:603.</a></li><li><a class="nounderline abstract_t">Barnham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire. J Infect 1989; 18:231.</a></li><li><a class="nounderline abstract_t">Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis 1991; 13:8.</a></li><li><a class="nounderline abstract_t">Stegmayr B, Björck S, Holm S, et al. Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand J Infect Dis 1992; 24:589.</a></li><li><a class="nounderline abstract_t">Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol 2005; 43:1789.</a></li><li><a class="nounderline abstract_t">Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792.</a></li><li><a class="nounderline abstract_t">Hasegawa T, Hashikawa SN, Nakamura T, et al. Factors determining prognosis in streptococcal toxic shock-like syndrome: results of a nationwide investigation in Japan. Microbes Infect 2004; 6:1073.</a></li><li><a class="nounderline abstract_t">Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J Pediatr 2004; 144:68.</a></li><li><a class="nounderline abstract_t">Sablier F, Slaouti T, Drèze PA, et al. Nosocomial transmission of necrotising fasciitis. Lancet 2010; 375:1052.</a></li><li><a class="nounderline abstract_t">Lamagni TL, Oliver I, Stuart JM. Global assessment of invasive group a streptococcus infection risk in household contacts. Clin Infect Dis 2015; 60:166.</a></li><li><a class="nounderline abstract_t">Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35:950.</a></li><li><a class="nounderline abstract_t">Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.</a></li><li><a class="nounderline abstract_t">Jordan HT, Richards CL Jr, Burton DC, et al. Group a streptococcal disease in long-term care facilities: descriptive epidemiology and potential control measures. Clin Infect Dis 2007; 45:742.</a></li></ol></div><div id="topicVersionRevision">Topic 3169 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25307276" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of invasive group A streptococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571429" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Invasive group A streptococcus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571429" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Invasive group A streptococcus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638193" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2659990" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25243426" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiac myocyte dysfunction induced by streptolysin O is membrane pore and calcium dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2682245" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Group A streptococcal infections and a toxic shock-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2218404" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Streptococcal serogroup A epidemic in Norway 1987-1988.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282471" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Streptococcus pyogenes and the toxic shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3890787" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Streptococcal myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184817" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Streptococcal toxic shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12985596" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3292661" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18611620" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Invasive group A streptococcal infection: New concepts in antibiotic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501331" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354465" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077718" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Persistent acylation of high-molecular-weight penicillin-binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2882731" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of antibiotics on toxin production and viability of Clostridium perfringens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7014632" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11691576" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809722" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serious group a streptococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608632" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785239" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333013" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness of adjunctive clindamycin inβ-lactam antibiotic-treated patients with invasiveβ-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080080" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764198" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Streptococcal toxic shock syndrome by an iMLS resistant M type 77 Streptococcus pyogenes in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068284" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902646" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Macrolide and Clindamycin Resistance in Group a Streptococci Isolated From Children With Pharyngitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902646" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Macrolide and Clindamycin Resistance in Group a Streptococci Isolated From Children With Pharyngitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28642756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High Prevalence of Macrolide-resistance and Molecular Characterization of Streptococcus pyogenes Isolates Circulating in China from 2009 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211672" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Necrotizing Soft-Tissue Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211672" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Necrotizing Soft-Tissue Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788397" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034881" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928291" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19788359" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intravenous immunoglobulin in children with streptococcal toxic shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609429" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8945593" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999628" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825042" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2323820" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113397" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607705" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912949" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532002" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Streptococcal infections of skin and soft tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8627025" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3076677" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Streptococcus pyogenes bacteraemia in Cambridge--a review of 67 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2663996" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2017638" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1465576" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15815000" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329511" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380776" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Factors determining prognosis in streptococcal toxic shock-like syndrome: results of a nationwide investigation in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14722521" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20304249" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nosocomial transmission of necrotising fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25258351" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Global assessment of invasive group a streptococcus infection risk in household contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355382" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068815" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712760" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Group a streptococcal disease in long-term care facilities: descriptive epidemiology and potential control measures.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
